Cyclic adenosine monophosphate (cAMP) therapy in chronic congestive heart failure. 69 patients with chronic heart failure were randomly divided into 2 groups. On the basis of routine treatment with digitalis, diuretics, and converting enzyme inhibitors, the treatment group was given cAMP 120 mg/d; the control group was given 100 mg dopamine plus dobutol. Treatment with butylamine 100 mg/d, the course of treatment was 7 days. Results: The total effective rates of the two groups were basically the same, but the effective and effective time of the cyclic adenosine monophosphate (cAMP) group were shorter than those of the control group; there was statistical significance between the two groups of Cabot carbon black. Conclusion: Cyclic adenosine monophosphate (cAMP) can be an effective and feasible method for the treatment of chronic congestive heart failure.
There were 69 patients, including 53 cases of coronary heart disease, 12 cases of coronary heart disease plus hypertensive heart disease, and 4 cases of dilated cardiomyopathy. Age ranged from 38 to 78 years old, with an average age of 51.8 years.
Principles of chronic congestive heart failure
Cyclic adenosine monophosphate (cAMP) is an important regulatory substance in cells and plays a wide range of physiological roles as the “second messenger” in cells. Animal experiments show that cAMP can enhance myocardial contraction. Silicone oil has a mild cardiotonic effect and can significantly increase the beating intensity and frequency of cultured cardiomyocytes. It has the effects of increasing coronary artery flow, protecting ischemic myocardium, relaxing peripheral blood vessels, reducing peripheral resistance, and reducing myocardial oxygen consumption. Dopamine and dobutamine, as β-receptor agonists, increase intracellular cAMP concentration through indirect effects, thereby exerting their pharmacological effects. Due to the reduced density of β-receptors in failing myocardium, the effect of such preparations is weakened. Therefore, β-adrenoceptor agonists can only produce short-term hemodynamic effects and are difficult to sustain for long-term use. There is no improvement in symptoms and exercise tolerance. Increasing the dose is ineffective and has side effects. (mainly ventricular arrhythmia) worsens and the mortality rate increases.
Cyclic adenosine monophosphate meglumine is a replacement product of adenosine monophosphate (AMP) drugs. After being added to cells, it can directly exert the effect of cAMP, activate slow channels, increase the influx of calcium ions, and produce positive Muscle effect. The β-receptor agonist needs to bind to the β-receptor on the myocardial cell membrane, activate adenosine cyclase through the receptor-G protein-adenosine cyclase (RGC) complex, and catalyze ATP to produce cAMP.
The apparent efficiency is 37.1%, the total effective efficiency is 85.7%
The results showed that cardiac function was significantly improved after treatment with cyclic adenosine monophosphate (cAMP), with a significant efficiency of 37.1% and a total effective rate of 85.7%. Compared with β-adrenoceptor agonists, the efficacy is roughly the same, but there are no obvious side effects. As a drug for the treatment of chronic congestive heart failure, cyclic adenosine monophosphate (cAMP) should be considered in patients with poor efficacy of digitalis or digitalis poisoning.
